Compounds > n(1),n(8)-diethylspermidine
Page last updated: 2024-12-07

n(1),n(8)-diethylspermidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N(1),N(8)-diethylspermidine: regulator of ornithine decarboxylase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID130340
CHEMBL ID18027
SCHEMBL ID4171429
MeSH IDM0144544

Synonyms (8)

Synonym
1,4-butanediamine, n-ethyl-n'-(3-(ethylamino)propyl)-
n(1),n(8)-diethylspermidine
CHEMBL18027
97141-40-7
n(1),n(8)-bis(ethyl)spermidine
SCHEMBL4171429
DTXSID20914110
n~1~-ethyl-n~4~-[3-(ethylamino)propyl]butane-1,4-diamine
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (24)

Assay IDTitleYearJournalArticle
AID96667Percentage of spermine after 48 hr exposure to the compound (100(30)uM ) in L1210 cells1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
A comparison of structure-activity relationships between spermidine and spermine analogue antineoplastics.
AID98715Growth inhibitory activity against L1210 cells (48h)1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
A comparison of structure-activity relationships between spermidine and spermine analogue antineoplastics.
AID147601Inhibition of ornithine decarboxylase (ODC)2001Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1
Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID160318Binding affinity values for polyamine transporter was determined1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
A comparison of structure-activity relationships between spermidine and spermine analogue antineoplastics.
AID97152Effect on Spermidine/Spermine-Acetyltransferase (SSAT ) at 10 uM at 48 hour in L1210 cells1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
A comparison of structure-activity relationships between spermidine and spermine analogue antineoplastics.
AID78587Cytokinetic effects on H82 small-cell lung tumor line (SCLC) after 96-h treatment; Cytostatic at <= 10 uM2001Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1
Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID98972Intracellular levels in L1210 cells following 500 uM exposure.1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
A comparison of structure-activity relationships between spermidine and spermine analogue antineoplastics.
AID212005The acute lethal dose administered as a single intraperitoneal injection1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
A comparison of structure-activity relationships between spermidine and spermine analogue antineoplastics.
AID80470Effect of exposure of H157 non-SCLC to compound (<10 uM) for 96-h, on natural polyamines and accumulation of the compound; Decrease2001Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1
Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID80476Cytokinetic effect on H157 non-small-cell lung tumor line (non-SCLC) after 96-h treatment; Cytotoxic at <10 uM2001Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1
Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID96680Percentage of spermine after 48 hr exposure to the compound (500(150)uM ) in L1210 cells1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
A comparison of structure-activity relationships between spermidine and spermine analogue antineoplastics.
AID99042Tested for inhibition of L1210 cell growth by the compound at a dose of 30 uM and after 48 hr1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthetic polyamine analogues as antineoplastics.
AID98716Growth inhibitory activity against L1210 cells (96h)1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
A comparison of structure-activity relationships between spermidine and spermine analogue antineoplastics.
AID97537Effect on S-Adenosyl-methionine decarboxylase (AdoMetDC) tested at 1 uM at 6 hour in L1210 cells1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
A comparison of structure-activity relationships between spermidine and spermine analogue antineoplastics.
AID98503Tested for inhibition of L1210 cell growth by the compound after 96 hr1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthetic polyamine analogues as antineoplastics.
AID96509Percentage of putrescine after 48 hr exposure to the compound (500(150)uM ) in L1210 cells1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
A comparison of structure-activity relationships between spermidine and spermine analogue antineoplastics.
AID80355Effect of exposure of H157 non-SCLC (<10 uM) for 96-h, and accumulation of compound was determined2001Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1
Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID200225Inhibition of Inhibition of rat liver form of S-adenosyl-methionine decarboxylase enzyme (AdoMet-DC)2001Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1
Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID96516Percentage of spermidine after 48 hr of exposure to the compound (100(30)uM ) in L1210 cells1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
A comparison of structure-activity relationships between spermidine and spermine analogue antineoplastics.
AID96529Percentage of spermidine after 48 hr of exposure to the compound (500(150)uM ) in L1210 cells1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
A comparison of structure-activity relationships between spermidine and spermine analogue antineoplastics.
AID201172Effect of 10 uM on spermine/spermidine-N-acetyltransferase (SSAT) induction in non-SCLC cells2001Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1
Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID98950Effect on ornithine decarboxylase (ODC) tested at 1 uM at 4 hour in L1210 cells1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
A comparison of structure-activity relationships between spermidine and spermine analogue antineoplastics.
AID96496Percentage of putrescine after 48 hr exposure to the compound (100(30)uM ) in L1210 cells1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
A comparison of structure-activity relationships between spermidine and spermine analogue antineoplastics.
AID212007The chronic lethal dose administered as intraperitoneal injection1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
A comparison of structure-activity relationships between spermidine and spermine analogue antineoplastics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (60.00)18.7374
1990's3 (30.00)18.2507
2000's1 (10.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.70 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.09 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
sym-homospermidine
sym-homospermidine: analog of spermidine isolated from sandal leaves (Santalum album L.); structure. sym-homospermidine : A polyazaalkane comprising undecane with three aza groups placed at the 1-, 6- and 11-positions.		1.9910polyazaalkane;
triamine
putrescine
[no description available]		1.9710alkane-alpha,omega-diamineantioxidant;
fundamental metabolite
spermidine
[no description available]		3.4780polyazaalkane;
triamine		autophagy inducer;
fundamental metabolite;
geroprotector
spermine
[no description available]		2.6730polyazaalkane;
tetramine		antioxidant;
fundamental metabolite;
immunosuppressive agent
amsacrine
Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.. amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.		1.9710acridines;
aromatic ether;
sulfonamide		antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
eflornithine
Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.. eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.		2.6630alpha-amino acid;
fluoroamino acid		trypanocidal drug
n(1),n(11)-diethylnorspermine
N(1),N(11)-diethylnorspermine: structure given in first source		3.110
n(1), n(12)-diethylspermine
N(1), N(12)-diethylspermine: structure in first source. N(1),N(12)-diethylspermine : A substituted spermine that is spermine in which a hydrogen attached to each of the primary amino groups has been replaced by an ethyl group.		4.1850polyazaalkane;
secondary amino compound;
substituted spermine;
tetramine		antineoplastic agent
dipropylenetriame
N-(3-aminopropyl)-1,3-propanediamine: structure in first source		1.9910polyazaalkanealgal metabolite;
plant metabolite
cycloheximide
Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.		1.9710antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol		anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor
melarsen oxide
melarsen oxide: inhibits glutathione reductase		3.110
colforsin
Colforsin: Potent activator of the adenylate cyclase system and the biosynthesis of cyclic AMP. From the plant COLEUS FORSKOHLII. Has antihypertensive, positive inotropic, platelet aggregation inhibitory, and smooth muscle relaxant activities; also lowers intraocular pressure and promotes release of hormones from the pituitary gland.		1.9710acetate ester;
cyclic ketone;
labdane diterpenoid;
organic heterotricyclic compound;
tertiary alpha-hydroxy ketone;
triol		adenylate cyclase agonist;
anti-HIV agent;
antihypertensive agent;
plant metabolite;
platelet aggregation inhibitor;
protein kinase A agonist
n(1),n(14)-bis(ethyl)homospermine
N(1),N(14)-bis(ethyl)homospermine: structure given in first source; depletes polyamines and inhibits the growth of tumor cells in tissue culture		3.4920
mdl 27695
MDL 27695: structure given in first source		3.110
s-adenosyl-3-thio-1,8-diaminooctane
S-adenosyl-3-thio-1,8-diaminooctane: structure given in first source		3.110
6-heptyne-2,5-diamine
6-heptyne-2,5-diamine: RN given refers to cpd without isomeric designation		1.9610
s-adenosyl-1,12-diamino-3-thio-9-azadodecane
S-adenosyl-1,12-diamino-3-thio-9-azadodecane: structure given in first source		3.110
mitoguazone
Mitoguazone: Antineoplastic agent effective against myelogenous leukemia in experimental animals. Also acts as an inhibitor of animal S-adenosylmethionine decarboxylase.. mitoguazone : A hydrazone obtained by formal condensation of the two carbonyl groups of methylglyoxal with the primary amino groups of two molecules of aminoguanidine.		3.110guanidines;
hydrazone		antineoplastic agent;
apoptosis inducer;
EC 4.1.1.50 (adenosylmethionine decarboxylase) inhibitor
bucladesine
Bucladesine: A cyclic nucleotide derivative that mimics the action of endogenous CYCLIC AMP and is capable of permeating the cell membrane. It has vasodilator properties and is used as a cardiac stimulant. (From Merck Index, 11th ed). bucladesine : A 3',5'-cyclic purine nucleotide that is the 2'-butanoate ester and 6-N-butanoyl derivative of 3',5'-cyclic AMP.		1.97103',5'-cyclic purine nucleotide
s-adenosylmethionine
(R)-S-adenosyl-L-methionine : An S-adenosyl-L-methionine that has R-configuration.. S-adenosyl-L-methionine zwitterion : A zwitterionic tautomer of S-adenosyl-L-methionine arising from shift of the proton from the carboxy group to the amino group.. (R)-S-adenosyl-L-methionine zwitterion : An S-adenosyl-L-methionine zwitterion that has R-configuration; major species at pH 7.3.. (S)-S-adenosyl-L-methionine zwitterion : An S-adenosyl-L-methionine zwitterion that has S-configuration; major species at pH 7.3.. S-adenosyl-L-methionine : A sulfonium compound that is the S-adenosyl derivative of L-methionine. It is an intermediate in the metabolic pathway of methionine.		1.9710organic cation;
sulfonium compound		coenzyme;
cofactor;
human metabolite;
micronutrient;
Mycoplasma genitalium metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia L 1210
[description not available]		03.0750
Opportunistic Infections
An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.		02.9210
Cancer of Lung
[description not available]		02.3720
Lung Neoplasms
Tumors or cancer of the LUNG.		02.3720
Carcinoma, Non-Small Cell Lung
[description not available]		01.9710
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		01.9710